Abstract:Small-cell lung cancer (SCLC) accounts for 13–15% of all new lung cancer cases in the US. The tumor has a tendency to disseminate early resulting in 80–85% of patients being diagnosed with extensive disease (ES-SCLC). Chemotherapy has provided SCLC patients considerable survival benefits over the past three decades. Nonetheless, most patients relapse and rarely survive beyond 2 years. Despite consistent overall response rates of ≥50%, until recently, median survival times and 2-year survivals only ranged between 7–10 months and 10–20%, respectively. Several chemotherapy agents possess activity against SCLC, both, as single agents and in combinations but etoposide-platinum emerged as the preferred first line regimen. Upon relapse, many patients remain candidates for additional therapy. However, the sensitivity of relapsed SCLC to further therapies is markedly reduced and dependent upon the level and duration of response to the initial treatment (platinum-sensitive vs. resistant relapse). Multiple factors suggest a therapeutic role for immunotherapy in SCLC:(1) SCLC has been associated with immune-mediated paraneoplastic processes (cerebellar degeneration, limbic encephalitis, and Lambert–Eaton syndrome) and patients presenting with these paraneoplastic syndromes have shown more favorable outcomes, suggesting an underlying immune response mechanism.(2) Comprehensive genomic profiling of SCLC indicates that the majority lack functional p53 (90%) and Rb1 (65%). These universal genetic aberrations facilitate poor genomic stability, thus perpetuating the generation of tumor associated antigens, amenable to targeting with immunotherapy.(3) SCLC has one of the highest mutational loads, likely a reflection of the myriad of insults inflicted by smoking-related carcinogens. The relationship between tumor mutational load and response to immune checkpoint inhibitors has been established in multiple solid tumors, including preliminary results in relapsed SCLC.In this manuscript, we review the early (some failed and discontinued, some partly successful, and still ongoing) attempts to incorporate immunotherapy (particularly vaccine based approaches) to the treatment of SCLC, and the latest attempts (mostly incorporating the use of checkpoint inhibitors), including those with favorable but preliminary results (CheckMate 032, Keynote 028 and 158), and those with more definitive positive (iMpower 133 and CASPIAN) and negative (CheckMate 331 and 451) results.

Treatment of extensive-stage small cell lung carcinoma: current status and future prospects

Treatment of Small Cell Lung Cancer: Recent Advances

Recent developments in the treatment of small cell lung cancer

Current Diagnosis and Management of Small-Cell Lung Cancer

Extensive‐stage Small‐cell Lung Cancer: Current Management and Future Directions

Current Management and Progress in Radiotherapy for Small Cell Lung Cancer

Update 2021: Management of Small Cell Lung Cancer

Current and future strategies in radiotherapy for small-cell lung cancer

Progress in the therapy of small cell lung cancer

The Evolving Scenario of ES-SCLC Management: From Biology to New Cancer Therapeutics

Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC)

Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer

Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer

Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review

Current Small Cell Lung Cancer Treatment In China

A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC)

Research progress in the treatment of small cell lung cancer

Current and future therapeutic approaches for the treatment of small cell lung cancer

Recent developments in limited stage small cell lung cancer

Immunotherapy for small cell lung cancer: the current state and future trajectories

Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion